
Human Microbiome Therapeutics Market Size, Share, and Outlook, H2-2025 Report- By Product (Probiotics, Prebiotics, Medical foods, Prescription drugs), By Application (Gastrointestinal disorders, Infectious diseases, Others) and Companies, 2021-2032
Description
Human Microbiome Therapeutics Market Outlook
The global Human Microbiome Therapeutics Market Size is valued at $245.6 Million in 2025 and is forecast to reach $1770.2 Million in 2032 at a CAGR of 32.6%.
The Human Microbiome Therapeutics Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Human Microbiome Therapeutics Market segments across 22 countries from 2021 to 2032. Key segments covered include By Product (Probiotics, Prebiotics, Medical foods, Prescription drugs), By Application (Gastrointestinal disorders, Infectious diseases, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Human Microbiome Therapeutics Market Insights, 2025
The Human Microbiome Therapeutics market is at the forefront of next-generation healthcare innovation, focusing on the role of gut, skin, and other microbiota in disease prevention and treatment. With growing evidence linking microbiome imbalances to chronic conditions such as inflammatory bowel disease, obesity, diabetes, and neurological disorders, therapeutic strategies are evolving rapidly. Interventions range from live biotherapeutic products and engineered probiotics to fecal microbiota transplantation (FMT) and microbiome-derived metabolites. Major pharmaceutical and biotech companies are investing in clinical trials to validate microbiome-based therapies, supported by a surge in microbiome sequencing and analytics capabilities. Personalized therapeutics tailored to an individual’s microbiome profile are a key emerging trend. Regulatory frameworks are evolving to address the unique challenges of live microbial therapeutics, potentially paving the way for broader commercialization in the near future.
Five Trends Shaping the Global Human Microbiome Therapeutics Market in 2025 and Beyond
The global Human Microbiome Therapeutics Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Human Microbiome Therapeutics Industry?
The Human Microbiome Therapeutics Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Human Microbiome Therapeutics Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Human Microbiome Therapeutics Market Segment Insights
The Human Microbiome Therapeutics Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Product (Probiotics, Prebiotics, Medical foods, Prescription drugs), By Application (Gastrointestinal disorders, Infectious diseases, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Human Microbiome Therapeutics Industry Value Chain
The chapter identifies potential companies and their operations across the global Human Microbiome Therapeutics Industry ecosystem. It assists decision-makers in evaluating global Human Microbiome Therapeutics Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Human Microbiome Therapeutics Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Human Microbiome Therapeutics Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Human Microbiome Therapeutics Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Human Microbiome Therapeutics Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Human Microbiome Therapeutics Market.
Europe Human Microbiome Therapeutics Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Human Microbiome Therapeutics Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Human Microbiome Therapeutics Industry competitiveness. The report analyses the key Human Microbiome Therapeutics Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Human Microbiome Therapeutics Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Human Microbiome Therapeutics Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Human Microbiome Therapeutics Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Human Microbiome Therapeutics Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Human Microbiome Therapeutics Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Human Microbiome Therapeutics Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes 4D pharma Plc, BiomX Inc, Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc, Evogene Ltd, Ferring BV, Finch Therapeutics Group Inc, Flightpath Biosciences, Johnson and Johnson Services Inc, Locus Biosciences Inc, MaaT Pharma, Microbiotica Ltd, OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc, Synlogic Inc, Takeda Pharmaceutical Co. Ltd, YSOPIA Bioscience. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Human Microbiome Therapeutics Market Scope
Leading Segments
By Product
Probiotics
Prebiotics
Medical foods
Prescription drugs
By Application
Gastrointestinal disorders
Infectious diseases
Others
Leading Companies
4D pharma Plc
BiomX Inc
Eligo Bioscience
ENTEROME SA
Evelo Biosciences Inc
Evogene Ltd
Ferring BV
Finch Therapeutics Group Inc
Flightpath Biosciences
Johnson and Johnson Services Inc
Locus Biosciences Inc
MaaT Pharma
Microbiotica Ltd
OptiBiotix Health Plc
PureTech Health Plc
Second Genome Therapeutics
Seres Therapeutics Inc
Synlogic Inc
Takeda Pharmaceutical Co. Ltd
YSOPIA Bioscience
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Human Microbiome Therapeutics Market Size is valued at $245.6 Million in 2025 and is forecast to reach $1770.2 Million in 2032 at a CAGR of 32.6%.
The Human Microbiome Therapeutics Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Human Microbiome Therapeutics Market segments across 22 countries from 2021 to 2032. Key segments covered include By Product (Probiotics, Prebiotics, Medical foods, Prescription drugs), By Application (Gastrointestinal disorders, Infectious diseases, Others), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Human Microbiome Therapeutics Market Insights, 2025
The Human Microbiome Therapeutics market is at the forefront of next-generation healthcare innovation, focusing on the role of gut, skin, and other microbiota in disease prevention and treatment. With growing evidence linking microbiome imbalances to chronic conditions such as inflammatory bowel disease, obesity, diabetes, and neurological disorders, therapeutic strategies are evolving rapidly. Interventions range from live biotherapeutic products and engineered probiotics to fecal microbiota transplantation (FMT) and microbiome-derived metabolites. Major pharmaceutical and biotech companies are investing in clinical trials to validate microbiome-based therapies, supported by a surge in microbiome sequencing and analytics capabilities. Personalized therapeutics tailored to an individual’s microbiome profile are a key emerging trend. Regulatory frameworks are evolving to address the unique challenges of live microbial therapeutics, potentially paving the way for broader commercialization in the near future.
Five Trends Shaping the Global Human Microbiome Therapeutics Market in 2025 and Beyond
The global Human Microbiome Therapeutics Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Human Microbiome Therapeutics Industry?
The Human Microbiome Therapeutics Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Human Microbiome Therapeutics Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Human Microbiome Therapeutics Market Segment Insights
The Human Microbiome Therapeutics Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Product (Probiotics, Prebiotics, Medical foods, Prescription drugs), By Application (Gastrointestinal disorders, Infectious diseases, Others). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Human Microbiome Therapeutics Industry Value Chain
The chapter identifies potential companies and their operations across the global Human Microbiome Therapeutics Industry ecosystem. It assists decision-makers in evaluating global Human Microbiome Therapeutics Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Human Microbiome Therapeutics Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Human Microbiome Therapeutics Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Human Microbiome Therapeutics Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Human Microbiome Therapeutics Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Human Microbiome Therapeutics Market.
Europe Human Microbiome Therapeutics Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Human Microbiome Therapeutics Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Human Microbiome Therapeutics Industry competitiveness. The report analyses the key Human Microbiome Therapeutics Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Human Microbiome Therapeutics Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Human Microbiome Therapeutics Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Human Microbiome Therapeutics Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Human Microbiome Therapeutics Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Human Microbiome Therapeutics Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Human Microbiome Therapeutics Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes 4D pharma Plc, BiomX Inc, Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc, Evogene Ltd, Ferring BV, Finch Therapeutics Group Inc, Flightpath Biosciences, Johnson and Johnson Services Inc, Locus Biosciences Inc, MaaT Pharma, Microbiotica Ltd, OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc, Synlogic Inc, Takeda Pharmaceutical Co. Ltd, YSOPIA Bioscience. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Human Microbiome Therapeutics Market Scope
Leading Segments
By Product
Probiotics
Prebiotics
Medical foods
Prescription drugs
By Application
Gastrointestinal disorders
Infectious diseases
Others
Leading Companies
4D pharma Plc
BiomX Inc
Eligo Bioscience
ENTEROME SA
Evelo Biosciences Inc
Evogene Ltd
Ferring BV
Finch Therapeutics Group Inc
Flightpath Biosciences
Johnson and Johnson Services Inc
Locus Biosciences Inc
MaaT Pharma
Microbiotica Ltd
OptiBiotix Health Plc
PureTech Health Plc
Second Genome Therapeutics
Seres Therapeutics Inc
Synlogic Inc
Takeda Pharmaceutical Co. Ltd
YSOPIA Bioscience
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
195 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Human Microbiome Therapeutics Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Human Microbiome Therapeutics Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Human Microbiome Therapeutics Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Human Microbiome Therapeutics Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Human Microbiome Therapeutics Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Product
- Probiotics
- Prebiotics
- Medical foods
- Prescription drugs
- By Application
- Gastrointestinal disorders
- Infectious diseases
- Others
- 6. Global Human Microbiome Therapeutics Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Human Microbiome Therapeutics Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Human Microbiome Therapeutics Market Trends and Growth Opportunities
- 6.2.1 North America Human Microbiome Therapeutics Market Outlook by Type
- 6.2.2 North America Human Microbiome Therapeutics Market Outlook by Application
- 6.3 North America Human Microbiome Therapeutics Market Outlook by Country
- 6.3.1 The US Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 6.3.2 Canada Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 6.3.3 Mexico Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 7. Europe Human Microbiome Therapeutics Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Human Microbiome Therapeutics Market Trends and Growth Opportunities
- 7.2.1 Europe Human Microbiome Therapeutics Market Outlook by Type
- 7.2.2 Europe Human Microbiome Therapeutics Market Outlook by Application
- 7.3 Europe Human Microbiome Therapeutics Market Outlook by Country
- 7.3.2 Germany Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 7.3.3 France Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 7.3.4 The UK Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 7.3.5 Spain Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 7.3.6 Italy Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 7.3.7 Russia Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 8. Asia Pacific Human Microbiome Therapeutics Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Human Microbiome Therapeutics Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Human Microbiome Therapeutics Market Outlook by Type
- 8.2.2 Asia Pacific Human Microbiome Therapeutics Market Outlook by Application
- 8.3 Asia Pacific Human Microbiome Therapeutics Market Outlook by Country
- 8.3.1 China Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 8.3.2 India Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 8.3.3 Japan Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 8.3.4 South Korea Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 8.3.5 Australia Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 8.3.6 South East Asia Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 9. South America Human Microbiome Therapeutics Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Human Microbiome Therapeutics Market Trends and Growth Opportunities
- 9.2.1 South America Human Microbiome Therapeutics Market Outlook by Type
- 9.2.2 South America Human Microbiome Therapeutics Market Outlook by Application
- 9.3 South America Human Microbiome Therapeutics Market Outlook by Country
- 9.3.1 Brazil Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 9.3.2 Argentina Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 10. Middle East and Africa Human Microbiome Therapeutics Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Human Microbiome Therapeutics Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Human Microbiome Therapeutics Market Outlook by Type
- 10.2.2 Middle East and Africa Human Microbiome Therapeutics Market Outlook by Application
- 10.3 Middle East and Africa Human Microbiome Therapeutics Market Outlook by Country
- 10.3.1 Saudi Arabia Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 10.3.2 The UAE Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 10.3.4 South Africa Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 10.3.5 Egypt Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Human Microbiome Therapeutics Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- 4D pharma Plc
- BiomX Inc
- Eligo Bioscience
- ENTEROME SA
- Evelo Biosciences Inc
- Evogene Ltd
- Ferring BV
- Finch Therapeutics Group Inc
- Flightpath Biosciences
- Johnson and Johnson Services Inc
- Locus Biosciences Inc
- MaaT Pharma
- Microbiotica Ltd
- OptiBiotix Health Plc
- PureTech Health Plc
- Second Genome Therapeutics
- Seres Therapeutics Inc
- Synlogic Inc
- Takeda Pharmaceutical Co. Ltd
- YSOPIA Bioscience
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.